Pasi Vottonen1. Show Affiliations » 1. Department of Ophthalmology, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland.
Abstract
Mesh: See more » Angiogenesis Inhibitors/economicsAngiogenesis Inhibitors/therapeutic useBevacizumab/economicsBevacizumab/therapeutic useCost-Benefit AnalysisEvoked Potentials, Visual/physiologyHumansNeurophysiologyRanibizumab/economicsRanibizumab/therapeutic useReceptors, Vascular Endothelial Growth Factor/therapeutic useRecombinant Fusion Proteins/economicsRecombinant Fusion Proteins/therapeutic useVascular Endothelial Growth Factor A/antagonists & inhibitorsWet Macular Degeneration/diagnosisWet Macular Degeneration/drug therapyWet Macular Degeneration/physiopathology
Substances: See more » Angiogenesis InhibitorsRecombinant Fusion ProteinsVEGFA protein, humanVascular Endothelial Growth Factor AafliberceptBevacizumabReceptors, Vascular Endothelial Growth FactorRanibizumab
Year: 2018 PMID: 29468838 DOI: 10.1111/aos.13706
Source DB: PubMed Journal: Acta Ophthalmol ISSN: 1755-375X Impact factor: 3.761